Search Results - manuel+penichet

2 Results

Sort By:

2021-043 NOVEL IGE ANTIBODIES FOR THE THERAPY OF CANCER

Researchers at UCLA’s David Geffen School of Medicine have designed three novel antibodies of the IgE class targeting antigens CD138, CD38, and transferrin receptor 1 (TfR1/CD71): cancer antigens present in various hematopoietic and/or solid tumors. There are several advantages of IgE class antibodies compared to the commonly used IgG class in...

Published: 2/15/2024 | Inventor(s): Manuel Penichet, Pierre Candelaria, Miguel Nava, Tracy Wells

Keywords(s): Cancer, Immunoglobulin G

Category(s): Platforms > Drug Delivery > Peptide Base, Therapeutics > Hematology

2014-845 ANTI-PSA IGG

Anti-PSA IgGSUMMARYResearchers at UCLA have developed chimeric IgG specific for prostate-specific antigen (PSA) in human and mouse cells.BACKGROUNDProstate-specific antigen (PSA) is a substance made by cells in the prostate gland. Physicians use high PSA levels (above 4 nanograms per milliliter) as a blood biomarker for prostate cancer. Given this,...

Published: 7/19/2023 | Inventor(s): Manuel Penichet, Tracy Wells, Gustavo Helguera

Keywords(s): Antibodies, Diagnostic Markers & Platforms, Diagnostic Platform Technologies (E.G. Microfluidics), Life Science Research Tools, Oncology

Category(s): Life Science Research Tools, Life Science Research Tools > Antibodies, Diagnostic Markers, Platforms > Diagnostic Platform Technologies, Therapeutics > Oncology